134 related articles for article (PubMed ID: 2834309)
1. Dosimetry and treatment planning for 90Y-labeled antiferritin in hepatoma.
Leichner PK; Yang NC; Frenkel TL; Loudenslager DM; Hawkins WG; Klein JL; Order SE
Int J Radiat Oncol Biol Phys; 1988 May; 14(5):1033-42. PubMed ID: 2834309
[TBL] [Abstract][Full Text] [Related]
2. Dosimetry of 131I-labeled antiferritin in hepatoma: specific activities in the tumor and liver.
Leichner PK; Klein JL; Siegelman SS; Ettinger DS; Order SE
Cancer Treat Rep; 1983; 67(7-8):647-58. PubMed ID: 6307515
[TBL] [Abstract][Full Text] [Related]
3. Yttrium-90 and iodine-131 radioimmunoglobulin therapy of an experimental human hepatoma.
Klein JL; Nguyen TH; Laroque P; Kopher KA; Williams JR; Wessels BW; Dillehay LE; Frincke J; Order SE; Leichner PK
Cancer Res; 1989 Nov; 49(22):6383-9. PubMed ID: 2553255
[TBL] [Abstract][Full Text] [Related]
4. Phase I-II studies of yttrium-labeled antiferritin treatment for end-stage Hodgkin's disease, including Radiation Therapy Oncology Group 87-01.
Vriesendorp HM; Herpst JM; Germack MA; Klein JL; Leichner PK; Loudenslager DM; Order SE
J Clin Oncol; 1991 Jun; 9(6):918-28. PubMed ID: 2033428
[TBL] [Abstract][Full Text] [Related]
5. Iodine 131 antiferritin, a new treatment modality in hepatoma: a Radiation Therapy Oncology Group study.
Order SE; Stillwagon GB; Klein JL; Leichner PK; Siegelman SS; Fishman EK; Ettinger DS; Haulk T; Kopher K; Finney K
J Clin Oncol; 1985 Dec; 3(12):1573-82. PubMed ID: 2415692
[TBL] [Abstract][Full Text] [Related]
6. Comparative tumor dose from 131I-labeled polyclonal anti-ferritin, anti-AFP, and anti-CEA in primary liver cancers.
Leichner PK; Klein JL; Fishman EK; Siegelman SS; Ettinger DS; Order SE
Cancer Drug Deliv; 1984; 1(4):321-8. PubMed ID: 6085756
[TBL] [Abstract][Full Text] [Related]
7. 90Yttrium antiferritin--a new therapeutic radiolabeled antibody.
Order SE; Klein JL; Leichner PK; Frincke J; Lollo C; Carlo DJ
Int J Radiat Oncol Biol Phys; 1986 Feb; 12(2):277-81. PubMed ID: 3005201
[TBL] [Abstract][Full Text] [Related]
8. Survival of patients with resistant Hodgkin's disease after polyclonal yttrium 90-labeled antiferritin treatment.
Herpst JM; Klein JL; Leichner PK; Quadri SM; Vriesendorp HM
J Clin Oncol; 1995 Sep; 13(9):2394-400. PubMed ID: 7666099
[TBL] [Abstract][Full Text] [Related]
9. The theoretical implications and experimental and clinical results of radiolabeled antiferritin.
Order SE
Acta Oncol; 1990; 29(6):689-94. PubMed ID: 2223137
[TBL] [Abstract][Full Text] [Related]
10. Variables affecting the tumor localization of 131I-antiferritin in experimental hepatoma.
Rostock RA; Klein JL; Kopher KA; Order SE
Am J Clin Oncol; 1984 Feb; 7(1):9-18. PubMed ID: 6695855
[TBL] [Abstract][Full Text] [Related]
11. Antiferritin IgG antibody for isotopic cancer therapy.
Order SE; Klein JL; Leichner PK
Oncology; 1981; 38(3):154-60. PubMed ID: 6259569
[TBL] [Abstract][Full Text] [Related]
12. Selective tumor localization in experimental hepatoma by radiolabeled antiferritin antibody.
Rostock RA; Klein JL; Leichner P; Kopher KA; Order SE
Int J Radiat Oncol Biol Phys; 1983 Sep; 9(9):1345-50. PubMed ID: 6885547
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, biodistribution, and dosimetry of specific and control radiolabeled monoclonal antibodies in patients with primary head and neck squamous cell carcinoma.
Maraveyas A; Stafford N; Rowlinson-Busza G; Stewart JS; Epenetos AA
Cancer Res; 1995 Mar; 55(5):1060-9. PubMed ID: 7866989
[TBL] [Abstract][Full Text] [Related]
14. Dosimetry and treatment planning in radioimmunotherapy.
Leichner PK; Yang NC; Wessels BW; Hawkins WG; Order SE; Klein JL
Front Radiat Ther Oncol; 1990; 24():109-20; discussion 121-2. PubMed ID: 2160407
[No Abstract] [Full Text] [Related]
15. Polyclonal 90Yttrium labeled antiferritin for refractory Hodgkin's disease.
Vriesendorp HM; Herpst JM; Leichner PK; Klein JL; Order SE
Int J Radiat Oncol Biol Phys; 1989 Oct; 17(4):815-21. PubMed ID: 2674084
[TBL] [Abstract][Full Text] [Related]
16. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
[TBL] [Abstract][Full Text] [Related]
17. Iodine 131 antiferritin, a new treatment modality in hepatoma: a Radiation Therapy Oncology Group study.
Hellman S
J Clin Oncol; 1985 Dec; 3(12):1569. PubMed ID: 2999345
[No Abstract] [Full Text] [Related]
18. Review of five consecutive studies of radiolabeled immunoglobulin therapy in Hodgkin's disease.
Vriesendorp HM; Morton JD; Quadri SM
Cancer Res; 1995 Dec; 55(23 Suppl):5888s-5892s. PubMed ID: 7493365
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of radiolabeled polyclonal antiferritin in patients with Hodgkin's disease.
Lai J; Quadri SM; Borchardt PE; Harris L; Wucher R; Askew E; Schweichel L; Vriesendorp HM
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3315s-3323s. PubMed ID: 10541380
[TBL] [Abstract][Full Text] [Related]
20. Radioimmunotherapy of human hepatocellular carcinoma xenografts with 131I-labelled antiferritin antibody.
Saiful Alam AF
Br J Cancer; 1991 Apr; 63(4):503-7. PubMed ID: 2021533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
